The new data supports the continued marketing of BioNTech's breast cancer subtyping assay as an alternative to IHC, and suggests added value for the test in assessing Ki-67 specifically.
The two partners hope to start a Phase I combination trial pairing Genentech's anti-PDL1 cancer immunotherapy Tecentriq with vaccines developed using BioNTech's IVAC Mutanome.
The deal will leverage BioNTech's IVAC Mutanome platform, which uses next-generation sequencing to identify targets for personalized mRNA-based vaccines.
The diagnostic, a real-time PCR kit for breast cancer stratification, is being reviewed under a special process for the approval of innovative products.
The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.